Palisade Bio (NASDAQ:PALI) Trading Down 2.5%

Palisade Bio, Inc. (NASDAQ:PALIGet Rating)’s share price fell 2.5% on Tuesday . The stock traded as low as $0.39 and last traded at $0.39. 47,201 shares were traded during mid-day trading, a decline of 96% from the average session volume of 1,094,799 shares. The stock had previously closed at $0.40.

Palisade Bio Trading Up 4.9 %

The stock’s 50-day simple moving average is $0.48 and its 200-day simple moving average is $0.79. The stock has a market cap of $8.95 million, a price-to-earnings ratio of -0.13 and a beta of 1.66.

Palisade Bio (NASDAQ:PALIGet Rating) last announced its earnings results on Friday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter. On average, equities research analysts forecast that Palisade Bio, Inc. will post -0.57 earnings per share for the current year.

Institutional Trading of Palisade Bio

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Palisade Bio by 11.5% in the first quarter. Vanguard Group Inc. now owns 271,604 shares of the company’s stock valued at $288,000 after buying an additional 28,014 shares in the last quarter. Sargent Investment Group LLC raised its stake in shares of Palisade Bio by 84.6% during the second quarter. Sargent Investment Group LLC now owns 240,000 shares of the company’s stock valued at $98,000 after acquiring an additional 110,000 shares during the last quarter. Finally, Altium Capital Management LP bought a new position in shares of Palisade Bio during the fourth quarter valued at $434,000. Institutional investors and hedge funds own 7.88% of the company’s stock.

Palisade Bio Company Profile

(Get Rating)

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery.

See Also

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.